By Colin Kellaher
Tonix Pharmaceuticals Holding said the Food and Drug Administration has accepted its application seeking approval of its TNX-102 SL product candidate for the chronic pain condition fibromyalgia.
Tonix on Tuesday said it expects the FDA to communicate a target action date and a decision on whether to grant priority review to the application in a so-called "Day 74" letter, which the agency issues within 74 days from its receipt of a submission.
The Chatham, N.J., company said TNX-102 SL, a non-opioid, sublingual pain reliever, has the potential to be the first member of a new class of analgesic drugs for fibromyalgia, adding that an FDA green light would make it the first new drug for treating fibromyalgia in more than 15 years.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 17, 2024 08:30 ET (13:30 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。